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ABSTRACT
Objective: This study was intended to investigate and characterize the phytoconstituents of Sargassum wightii, evaluate its antidiabetic and anti-
inflammatory potential under in silico and in vitro conditions.
Methods: The marine algae S. wightii was extracted with ethanol. The ethanolic extract was screened for various phytoconstituents, quantified for 
total flavonoid, and polyphenol content. Fourier transform infrared (FT-IR) and mass spectrometry were used for characterizing the ethanolic extract. 
The antidiabetic potential of the phytoconstituents was analyzed by molecular docking and enzyme inhibition assays. The anti-inflammatory potential 
was evaluated by albumin denaturation assay.
Results: The phytochemical screening revealed the presence of flavonoids, polyphenols, alkaloids, tannins, carbohydrates, proteins, oils, and fat 
present in the ethanol extract. The FT-IR analysis showed the presence of α,b unsaturated ketone, alcohol, and ether groups in the extract. MS 
analysis identified l - (+) - ascorbic acid 2, 6 dihexadeconoate and dotriacontyl isopropyl ether in the ethanolic extract. The molecular docking studies 
revealed that l - (+) - ascorbic acid 2, 6 dihexadeconoate interacted with both α-amylase and α-glucosidase with a consensus score of 5. The results 
of in vitro analysis showed that the ethanolic extract exhibited strong inhibitory activity on α-amylase (inhibitory concentration [IC50] 8 mg/ml) and 
α-glucosidase (IC50 6 mg/ml), respectively. The ethanolic extract also inhibited the formation of advanced glycation end products (IC50 10 mg/ml). 
Further, the ethanolic extract inhibited the denaturation of albumin (IC50 2.5 mg/ml) thereby revealing the anti-inflammatory potential of S. wightii.
Conclusion: Hence, it can be concluded that S. wightii possesses antidiabetic and anti-inflammatory potential which may be due to the presence of 
l - (+) - ascorbic acid 2, 6 dihexadeconoate and flavonoids, polyphenols, alkaloids, tannins, carbohydrates, proteins, oils, and fat present in the extract.
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INTRODUCTION
Diabetes, chronic disorder of the carbohydrate metabolism is projected 
as the 7th major cause of death worldwide, accounting for 5.1 million 
deaths in 2013 [1]. Diabetes accounts for 12.3% (673 billion USD) of 
global health-care expenses which is expected to reach 802 billion USD 
by 2040 [2]. The complications of diabetes include blindness, heart 
attack, kidney failure, stroke, and leg amputation [3]. Management 
of hyperglycemia is the major challenge in the treatment of diabetes. 
Chronic hyperglycemia causes the nonenzymatic glycation of serum 
proteins, resulting in the formation of advanced glycation end products 
(AGE) [4]. Glycated albumin is responsible for complications such as 
diabetic retinopathy, diabetic nephropathy, atherosclerotic lesions, 
insulin insensitivity, oxidative stress, and inflammation [5,6].
Oral hypoglycemic drugs are widely employed in the management of 
diabetes. These hypoglycemic drugs target the two major enzymes, 
namely, pancreatic α-amylase and intestinal α-glucosidase to regulate the 
postprandial blood sugar level [7]. To overcome the adverse side effects 
of synthetic hypoglycemics, medicinal plants and herbs are explored to 
identify a suitable alternate in the management of diabetes [8,9]. Marine 
seaweeds are a prolific source of potential secondary metabolites which 
provide lead compounds in drug development. Seaweeds are widely 
utilized as food in coastal areas of Asian countries where the prevalence 
of diabetes is less than the western world. Sargassum wightii is a marine 
algae, which possesses antibacterial, anti-Alzheimer, antiasthmatic, and 
antitumor activities [10-12]. Although, previous studies have reported 
the hypoglycemic activity of S. wightii [13] the active ingredient and the 
mechanism of action are still not reported. Hence, this study is intended 
to isolate and characterize the active ingredient(s) of S. wightii, to 
analyze its interaction with the critical enzymes (α-amylase and 
α-glucosidase) by molecular docking and to evaluate its antidiabetic 
potential under in vitro conditions.
METHODS
Seaweed collection and extraction
The seaweed S. wightii was collected from the Mandapam coastal 
region of Tamil Nadu, India. It was identified and authenticated by 
Dr. Saravanan, Scientist, CMFRI, Mandapam, Tamil Nadu, India. The 
collected seaweed was washed thoroughly to remove debris and shade 
dried, milled in an electric grinder. The dried algal powder (100 g) 
was extracted with ethanol (300 ml) for 72 hrs in an orbital shaker. 
The mixture was filtered, and the filtrate was evaporated in a rotary 
evaporator. The dried extract was used for further studies.
Phytochemical screening
The phytochemical composition of the ethanol extract was 
determined [14]. Quantification of flavonoids and polyphenols.
The total polyphenol content was determined using the Folin-Ciocalteu 
method [15]. In brief, different concentrations of the ethanolic extract 
(100,200,300,400,500 µg/ml) were mixed with 500 µl of FCP and 
150 µl of sodium carbonate (2%) and incubated for 2 hrs in the dark. 
The absorbance of the samples was read at 760 nm in a Multimode 
plate reader (Perkin Elmer). A blank devoid of algal extract served as 
negative control and gallic acid served as positive control.
The flavonoid content was determined according to [16]. In brief, 
different concentrations of the ethanolic extract (100-500 µg/ml) were 
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added with 100 µl of aluminum chloride (10%) and 100 µl of sodium 
acetate (1 M) and incubated for 30 minutes. The absorbance was read 
at 415 nm in a multimode plate reader (Perkin Elmer). A blank devoid 
of algal extract served as negative control. Quercetin was used as 
positive control.
Fourier transform infrared (FT-IR) and high-performance liquid 
chromatography (HPLC) analysis
The dried ethanolic extract (10 mg) of S. wightii was mixed 
with 10 mg of KBr and subjected to FT-IR analysis in Jasco FT-IR 
4600 series. HPLC separation was carried out in Shimadzu HPLC 
9A series (Japan) equipped with LC 20AD binary gradient pump, 
RF-fluorescence detector, and SPD- M20A diode array detector. 
The reverse phase separation was done in enable C18 G column 
of 250×4.6 mm of particle size 5 µm with a C18 guard column 
(3.9×20 mm) of particle size 4 µm maintained at 37°C with a flow 
rate of 1 ml/minute. The compounds in the ethanolic extract were 
separated using Acetonitrile and water in the ratio 30:70. The 
injection volume was 20 µl, and the monitoring was done by the 
diode array detector set in the acquisition range of 200-700 nm. The 
total running time was set for 25 minutes. The retention time (RT) of 
the compounds was recorded [17].
Mass spectrometry analysis of S. wightii
The chemical composition and mass of compounds in the ethanolic 
extract was detected in the mass spectrometer of Shimadzu (GC-MS QP 
2010 ULTRA) equipped with a direct injection port. The sample was 
injected directly and the emerging fragment ion pattern was collected. 
The ion source temperature was maintained at 200°C, and the interface 
was maintained at 250°C. The mass spectrometric voltage was set at 
70eV. The National Institute of Standards and Technologies (NIST14) 
database was used to identify the separated peaks.
In silico analysis of S. wightii bioactives
Preparation of protein
The X-ray crystal structures of human α-amylase and α-glucosidase (PDB 
id: 5EOF and 2QLY) were retrieved from Protein Data Bank. The SYBL 
X1.3 Protein preparation program was used to prepare the proteins. 
The removal of small molecules, water, the addition of hydrogen, and 
assigning bond orders to the PDB-derived protein structure was carried 
out. The resulting protein structures were used for the in silico study.
Preparation of ligand
The 3D structures of l - (+) - ascorbic acid 2, 6 dihexadeconoate 
and dotriacontyl isopropyl ether were retrieved from pubchem 
(PubchemCID: 54686917 and 91692940) and used for the interactive 
analysis.
Molecular docking
The SYBL X1.3 dock suite program was utilized for analyzing the 
interaction of  l - (+) - ascorbic acid 2, 6 dihexadeconoate and dotriacontyl 
isopropyl ether with α-amylase and α-glucosidase. The induced fit 
docking protocol of SYBL was used to evaluate the interaction between 
the ligands and the proteins. The best interaction was identified based 
on the total score and consensus score (C score) generated by the SYBL 
software.
Determination of in vitro antidiabetic activity
Inhibition of α-amylase activity
The inhibition of α-amylase by the ethanolic extract of S. wightii was 
evaluated as described previously [18]. In brief, 500 µl of the extract 
(2-8 mg/ml) was incubated with 500 µl of α-amylase (0.5 mg/ml in 
0.02 mM phosphate buffer, pH6.9) for 10 minutes at 25°C. Following 
this 500 µl of starch solution (1% in 0.02 mM phosphate buffer, pH6.9) 
was added and incubated for 10 minutes at 25°C. After incubation, the 
reaction was terminated by the addition of 1 ml of Dinitrosalicylic acid 
and the tubes were placed in a boiling water bath for 5 minutes. The 
contents were cooled and diluted by adding 5 ml of distilled water. The 
absorbance was read at 540 nm. A control with all the reaction contents, 
but lacking the extract was prepared which represented 100% enzyme 
activity. The assay was done in triplicate, and the values represent 
mean±standard deviation (SD).
Inhibition of α-glucosidase activity
The efficiency of the algal extract to inhibit α-glucosidase was 
evaluated [19]. In brief, different concentrations (2-10 mg/ml) of the 
algal extract were incubated with 1 ml of maltose (2% solution in 0.2 M 
Tris buffer) for 5 minutes at 37°C. 1 ml of α-glucosidase (1 U/ml) was 
added to initiate the reaction. The reaction mixture was incubated for 
40 minutes at 35°C. After incubation, 2 ml of 6N HCl was added to the 
reaction mixture and the absorbance was read at 540 nm. A control with 
all the reaction contents, but lacking the extract was prepared which 
represented 100% enzyme activity. The assay was done in triplicate 
and the values represent mean±SD.
Assessment of antiglycation activity
The antiglycation activity of the algal extract was evaluated based 
on previous studies [20] with some modification. In brief, different 
concentration (4-16 mg/ml) of the algal extract was incubated with 
400 µl of glucose solution (5 mM) and 500 µl of BSA (1 mg/ml) for 24 hrs 
at 60°C in an incubator. The reaction was terminated by the addition of 
10 µl TCA (100% w/v), and the reaction mixture was incubated at 4°C 
for 10 minutes. Following incubation, the contents were centrifuged at 
13,000 rpm for 5 minutes and the precipitate obtained was dissolved in 
alkaline PBS (pH 10) and the glycated BSA was quantified by measuring 
the absorbance at 440 nm. A negative control with 500 µl of BSA 
replacing the algal extract and a blank with all the reaction contents but 
lacking the extract was prepared. The assay was done in triplicate and 
the values represent mean±SD.
Anti-inflammatory activity
Inhibition of albumin denaturation
The anti-inflammatory efficiency of the algal extract was analyzed by 
the inhibition of albumin denaturation based on previous protocol [21] 
with slight modification. Different concentration (500 µg-2 mg/ml) of 
the algal extract was incubated with 500 µl of BSA (1%) for 20 minutes 
at 37°C followed by heating at 51°C for 20 minutes. The reaction 
contents were cooled and the turbidity developed was measured 
spectrophotometrically at 660 nm. A control with all the reaction 
contents, but lacking the extract was prepared which represented 
100% enzyme activity. The assay was done in triplicate, and the values 
represent mean±SD.
RESULTS
For the current study, the ethanolic extract of S. wightii was 
characterized, and the antidiabetic and anti-inflammatory activity of 
S. wightii was evaluated by in vitro studies. The extraction of the algae 
by ethanol yielded 300 mg of dried extract. The extract was further 
analyzed. The results of phytochemical analysis (Table 1) of the ethanol 
extract indicated the presence of flavonoids, polyphenols, alkaloids, 
tannins, carbohydrates, proteins, oils, and fat.
Table 1: Preliminary analysis of phytochemicals from 












+: Presence, ++: Moderate, +++: High, -: Absence
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The quantification of secondary metabolites namely flavonoids and 
polyphenols showed that S. wightii is a good source of these metabolites. 
The polyphenol content was found to vary in the range of 21-55.2 µg 
and the flavonoid content was between 40 and 133 µg in 100-500 mg of 
the algal extracts. The strong peaks observed in FT-IR analysis revealed 
the presence of C-O stretching of alcohol (3346 cm−1), C-O stretching 
of acid (2979 cm−1), C-O stretching of ether (1251 cm−1), and α, b 
unsaturated ketone (1639 cm−1). The HPLC chromatogram showed the 
presence of two prominent compounds with retention time 20.75 and 
22.739 minutes (Fig. 1).
The mass spectrometry analysis (Fig. 2) of the ethanol extract 
confirmed the presence of these two compounds and based on the ion 
chromatogram pattern and NIST14 library search these compounds 
were identified as dotriacontyl isopropyl ether and ascorbic acid 2, 6 
dihexadeconoate with M.wt. 508 and 652, respectively.
The interaction of these compounds with α-amylase and α-glucosidase 
was analyzed in silico using the SYBL X 1.3 docking software. The 
results of the interaction (Fig. 3) showed that l - (+) - ascorbic acid 2, 
6 dihexadeconoate interacted with both α-amylase and α-glucosidase 
with a total score of 3.216 and 10.87, respectively, whereas the other 
compounds (dotriacontyl isopropyl ether) did not show any interaction 
with both the enzymes analyzed.
The antidiabetic activity of the ethanolic extract was determined by its 
potential in inhibiting the enzymes α-amylase and α-glucosidase, which 
are responsible for the postprandial hyperglycemia in diabetes. The 
Fig. 2: Mass spectrometry analysis of ethanolic extract. (a) Ion chromatogram of dotriacontylisopropyl ether, (b) Ion chromatogram of 
ascorbic acid 2, 6 dihexadeconoate, (c) structure of dotriacontylisopropyl ether, (d) structure of ascorbic acid 2, 6 dihexadeconoate
a b
c d
Fig. 1: Characterisation of ethanolic extract of Sargassum wightii. (a) Quantification of flavonoids in 100-500 mg of ethanol 
extract, (b) quantitative analysis of polyphenols in 100-500 mg of ethanol extract. The values represent mean±standard deviation, 
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ethanolic extract exhibited a dose-dependent inhibition of α-amylase 
ranging from 16.76% at 1 mg/ml to 50.53% at 8 mg/ml (Fig. 4a). The 
extract exhibited an inhibitory concentration (IC50) value of 8 mg/ml. In 
case of α-glucosidase (Fig. 4b), the ethanol extract exhibited significant 
inhibition with 90.1% at 10 mg/ml to 13.166% at 2 mg/ml. The IC50 was 
determined as 6 mg/ml. The protective effect of the ethanolic extract 
by inhibiting the formation of advanced glycation end products was 
analyzed. The extract exhibited good inhibition against the glycation 
of albumin. The inhibition of glycation (Fig. 4c) varied with increasing 
dosage. The inhibition of glycation was 28.23% at 4 mg/ml and 
increased to 50% at 10 mg/ml. The IC50 of the extract was 10 mg/ml. 
The anti-inflammatory activity of the ethanol extract was analyzed 
based the inhibition of albumin denaturation. The ethanolic extract 
exhibited 58.69% of inhibitory activity at 3 mg/ml. The IC50 value of the 
extract was observed at 2.5 mg/ml (Fig. 4d).
DISCUSSION
Diabetes is an endocrine disorder causing premature death globally. 
Hyperglycemia resulting from uncontrolled postprandial blood sugar 
is the major challenging factor in diabetes. Although considerable 
advancements have been made in the biomedical field, the management 
of blood glucose is quite challenging. The excess of blood sugar causes 
glycation of hemoglobin, resulting in the formation of reactive oxygen 
species (ROS) [22]. The generation of ROS leads to denaturation of 
proteins resulting in prolonged inflammation, delayed wound healing, 
micro, and macrovascular changes. One of the recent strategies adopted 
in the management of diabetes involves the inhibition of α-amylase and 
α-glucosidase thereby regulating the blood glucose release. This study 
is an attempt to find a suitable natural alternate source of marine origin 
for the management of diabetes.
In this study, the effect of the ethanol extract of S. wightii in inhibiting 
α-amylase and α-glucosidase, prevention of AGE formation and anti-
inflammatory activity was evaluated under in vitro conditions. The 
phytochemical screening of the algal extract showed the presence 
of various phytoconstituents which are in agreement with earlier 
studies [23]. The quantification of flavonoids and polyphenols shows 
that S. wightii is rich in metabolites which are an important source 
of antioxidant molecules and are efficient free radical scavengers. 
Seaweeds are rich in antioxidants which may be attributed to their 
flavonoid and polyphenol content [24,25]. The FT-IR analysis confirmed 
the presence of various functional groups which is inconsistent 
with previous study [26]. The HPLC analysis showed the presence 
of two major compounds which were identified as dotriacontyl 
isopropyl ether and l-(+) -ascorbic acid 2, 6 dihexadeconoate by mass 
spectrometry. The identification of these compounds by MS analysis 
supports the FT-IR data which showed the presence of α, b unsaturated 
ketone (1639 cm−1) group and hydroxy groups at 1639 and 3346 cm−1 
which are present in ascorbic acid 2, 6 dihexadeconoate and the ether 
group at 1251 cm−1 present in Dotriacontyl isopropyl ether. Further 
Ascorbic acid 2, 6 dihexadeconoate is reported to confer wound healing 
property [27], antibacterial [28] and antitumor [29] properties. The 
characterization studies were followed by the in silico analysis where 
the interaction of ascorbic acid 2, 6 dihexadeconoate and dotriacontyl 
isopropyl ether with α-amylase and α-glucosidase was analyzed. The 
interaction study revealed that Ascorbic acid 2, 6 dihexadeconoate 
interacted with α-amylase and α-glucosidase efficiently with an SYBL 
C score of 4 and 5, respectively. The active site of α-amylase harbors 
the amino acids GLU 233, ASP 300 and ASP 197. These amino acids 
are essential for the breakdown of sugar residues by the enzyme. 
Ascorbic acid 2, 6 dihexadeconoate is found to interact with GLU 233 
in the active site of α-amylase, thereby inhibiting the binding of sugar 
molecule to the enzyme. Thus, the interaction results put forth that 
the inhibition exerted by S. wightii on α-amylase is mediated through 
the binding of ascorbic acid 2, 6 dihexadeconoate to GLU 233 in the 
active site. Similarly ascorbic acid 2, 6 dihexadeconoate interacted with 
α-glucosidase with a SYBL C score of 5 through the residues ASN 621 
and ARG 624. The docking study further revealed that dotriacontyl 
isopropyl ether present in the algal extract did not interact with both 
the enzymes analyzed. Thus, the interaction studies showed that the 
inhibition exhibited by the algal extract on α-amylase and α-glucosidase 
is mediated through ascorbic acid 2, 6 dihexadeconoate and not by 
dotriacontyl isopropyl ether.
The algal extract showed potent inhibition of α-amylase and 
α-glucosidase. Although previous studies have reported the inhibitory 
activity of methanol and ethyl acetate extracts of S. wightii against these 
enzymes, the compounds involved and the mechanism varies [30,31]. 
The inhibition of formation of AGE by the algal extract further supports 
its antidiabetic activity. The analysis of anti-inflammatory activity of 
S. wightii showed that the compounds of the algae offer protection 
against denaturation of proteins thus preventing inflammation of serum 
proteins. Denaturation of proteins causes a loss of their biological 
function and also leads to micro and macrovascular complications in 
diabetes. The inhibition of albumin denaturation suggests that can 
Fig. 4: Analysis of antidiabetic and anti-inflammatory potential 
of ethanolic extract. (a) Analysis of α amylase inhibitory activity 
of ethanolic extract in varying concentration (2-8 mg/ml), 
(b) analysis of α glucosidase inhibitory activity of ethanolic 
extract in varying concentration (2-10 mg/ml), (c) inhibition 
of protein glycation by ethanolic extract (4-10 mg/ml), 
(d) inhibition of albumin denaturation by ethanolic extract 
(1-3 mg/ml). Results expressed are mean±standard deviation
a b
dc
Fig. 3: Interaction studies of dotriacontylisopropyl ether 
and ascorbic acid 2, 6 dihexadeconoate with α amylase 
and α glucosidase. (a) Interaction of ascorbic acid 2, 6 
dihexadeconoate with α amylase, (b) interaction of ascorbic 
acid 2, 6 dihexadeconoate with α glucosidase (c) interaction of 
dotriacontylisopropyl ether with α amylase, (d) interaction of 
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limit the inflammatory response generated by proteases and enzymes 
in tissue inflammation [32]. Although similar studies [13,30] have 
reported the antidiabetic property of S. wightii, the potential bioactive 
compound and the mechanism of interaction were unrevealed. Thus, 
the current study has enabled in identifying the major bioactive 
compound and also the mechanism of its action in functioning as an 
antidiabetic compound. As the use of herbal plants in the management 
of diabetes is gaining momentum [33], the current study throws light on 
the antidiabetic potential of S. wightii which can be utilized efficiently 
in the treatment of diabetes. The in vitro analysis of antidiabetic and 
anti-inflammatory activity of S. wightii revealed that the algae not only 
possess potent inhibitors of α-amylase and α-glucosidase but also 
can offer protection from inflammatory response which alleviates the 
complications of diabetes.
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